Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Grindeks says Meldonium should not be included in prohibited list
The company said meldonium as an active substance is widely available for purchase on the internet by several international firms. Grindeks noted that there are plenty of sources
The company said meldonium as an active substance is widely available for purchase on the internet by several international firms. Grindeks noted that there are plenty of sources
Medivation can now go ahead with the phase II clinical trial in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and other studies that cross refer
MEDI-551 is an anti-CD19 monoclonal antibody indicated to treat neuromyelitis optica and neuromyelitis optica spectrum disorders. The drug is presently in phase IIb clinical development for treating NMO,
The companies said they will integrate their European vaccine operations into their global operations, manage their own portfolios separately, and pursue separate strategies for growth. Sanofi Pasteur MSD
The company expects to report top-line data from the study in the third quarter of this year. Under the phase 2 ReVEAL study, the company will assess the
The company is now eligible for several development incentives, including tax credits and reduced filing fees for clinical trials carried out in the US. If FDA approves SOR-C13
The agreement covers the compound BI655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. BI 655066 selectively blocks IL-23, a key protein involved in skin
Rintega (rindopepimut) is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII, a functional and permanently activated mutation of the epidermal growth factor receptor (EGFR) which has
Two doses of the drug were tested against a placebo and an oral antiviral called ribavarin to evaluate their effect on survival of immune-deficient mice infected with Zika
Nucala, which is administered once every four weeks by injection, maintained its risk/benefit profile over an extended 52-week period. The company enrolled a total of 651 patients in